PE-22-28
PE-22-28 is a synthetic analogue of spadin, a naturally occurring peptide derived from sortilin that acts as a TREK-1 potassium channel blocker. By blocking TREK-1, it mimics the antidepressant mechanism and also appears to promote neuroplasticity via TrkB receptor activation, the same receptor targeted by BDNF and ketamine.
In research contexts it has shown rapid-acting antidepressant and cognitive-enhancing effects. In self-experimentation circles it is used as a nootropic and mood peptide, often anecdotally described as producing a subtle clarity and resilience rather than a stimulant or euphoric effect.
PE-22-28 is chosen by users who want something aimed at the cognitive and mood side of performance rather than physique directly. The appeals include: faster-acting than SSRIs, injectable rather than chronic oral CNS medication, and a mechanism that aligns with neuroplasticity narratives that circulate in the smarter corners of the self-experimentation community.
- Reconstitute with bacteriostatic water per vial instructions; swirl gently.
- Most self-experimenters use subcutaneous injection at 100–250 mcg per dose.
- Dosing frequency varies widely in practice; some use daily, others use several times per week.
- This is a genuine research compound with limited human data. Start conservatively and do not combine with multiple CNS-active compounds without understanding the interaction landscape.
Reports in self-experimentation circles tend to describe subtle clarity and emotional resilience rather than dramatic mood shifts. If it helps, users notice it in how they handle training stress and cognitive load rather than in a euphoric or obviously stimulant way.
Use context
PE-22-28 occupies the overlap between serious nootropic peptide research and performance culture. It is not primarily a body-composition compound. Users who reach for it are usually dealing with the mood and cognitive toll of demanding training and AAS use: blunted motivation, emotional flatness, and difficulty maintaining the mental drive that physique goals require over years.
The mechanism is genuinely interesting. TREK-1 is a potassium channel expressed widely in the brain that, when blocked, produces antidepressant-like effects in animal models. TrkB activation (the BDNF receptor) is associated with neuroplasticity and the kind of adaptive brain states that hard training, sleep disruption, and caloric deficit tend to work against.
Stacking it with other CNS-active compounds without understanding which compound is doing what. Treating limited animal research as a complete safety picture. Expecting dramatic mood changes rather than the subtle effects that most honest users report.
Compared with Semax or Selank (other mood/nootropic peptides), PE-22-28 addresses a different mechanism. Compared with conventional antidepressants, the attraction is faster onset and injectable format. It is a genuine pharmacological compound with a specific CNS target, not a supplement.
Limited known side effect profile due to minimal human data
Theoretically possible CNS interactions when stacked with other neuroactive compounds
mood and cognitive function trend
History of psychiatric conditions without professional guidance
Stacking with SSRIs or other antidepressants without understanding the TREK-1/TrkB interaction